Quintiles and Archimedes announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies. Through this partnership, Quintiles will incorporate Archimedes’ healthcare modeling technology, the ARCHeS Innovator, and expertise into its existing solutions that span the product lifecycle.
“ARCHeS Innovator is a tremendous tool for capturing predictive simulations from real-world research, which is vital to helping biopharma improve efficiency and productivity in the New Health,” said Rick Sax, Global Head of Integrated Clinical Services for Quintiles. “Turning data into insights will allow customers to make faster, better decisions across the product lifecycle and increase their probability of success.”
Quintiles will promote and provide access to ARCHeS Innovator, a Software as a Service (SAAS) solution that gives users direct access to the Archimedes Model. The Archimedes Model is a full-scale computer simulation model of human physiology, diseases, behaviors, interventions, and healthcare systems. Through advanced methods of mathematics, computing, and data systems, the Model enables users to run clinically realistic virtual trials that drive better decisions in health and economic outcomes research, comparative effectiveness research, clinical trial design, and portfolio management.
Mika Newton, Vice President, ARCHeS & Consulting Business Leader for Archimedes, said: “Biopharma companies are under enormous pressure to maximize the efficiency and strategic positioning of products they are developing and marketing. This partnership between Archimedes and Quintiles makes advanced simulation modeling and premier medical evidence accessible and fully integrated into customers’ clinical research and commercial activities.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.